BioCentury | Jul 28, 2017
Company News

Miltenyi acquires Living Pharma and its CAR T technology

...The Lentigen Technology Inc. subsidiary of Miltenyi Biotec GmbH (Bergisch Gladbach, Germany) acquired immunotherapy company Living...
...CAR (AT-CAR) engineered T cell therapy technology. The companies will continue developing AT-CAR technology using Lentigen’s...
BioCentury | Sep 8, 2014
Company News

Opus Bio, Miltenyi Biotec deal

...single-gene diseases and disorders. Miltenyi will operate the business from its newly formed U.S. subsidiary, Lentigen...
BioCentury | Aug 7, 2014
Distillery Techniques

Technology: Markers

...Aug. 7, 2014 Methods covering the production and application of BaEV lentivirus patented; licensed to Lentigen Corp....
BioCentury | May 6, 2013
Company News

Lentigen, Nanolek LLC deal

...in Kirov, Russia. Under the deal, which is expected to be signed late this year, Lentigen...
...use in producing the vaccine. The VLP-based vaccine is produced from cell lines generated using Lentigen's...
...for 2015. Nanolek builds biological production facilities in Kirov, Russia, based on nanotechnologies and nanomaterials. Lentigen Corp....
BioCentury | Feb 25, 2013
Clinical News

LG631-CD34 regulatory update

...variant of methylguanine methyltransferase ( MGMT ) is in Phase I testing for the indication. Lentigen Corp....
BioCentury | May 3, 2010
Company News

Lentigen, IAVI deal

...Lentigen and the nonprofit will design a preventative HIV vaccine using Lentigen's synthetic lentiviral mimicking technology...
...mimicking technology and conduct preclinical testing under an 18-month deal. Financial terms were not disclosed. Lentigen Corp....
BioCentury | Feb 9, 2009
Company News

Expression Therapeutics, Lentigen deal

...Expression Therapeutics will use its high expression Factor VIII technology with Lentigen's protein expression and gene...
...Ownership of IP and financial terms were not disclosed. Expression Therapeutics LLC , Tucker, Ga. Lentigen Corp....
BioCentury | May 26, 2008
Finance

Ebb & Flow

...the U.S. government. ImmunoVaccine had $250,000 in 2007 revenue, primarily from partnerships. Gene delivery company Lentigen...
BioCentury | Apr 7, 2008
Company News

Lentigen, University of Cambridge deal

...lentiviral vector platform to develop pandemic and seasonal influenza vaccines. Further terms were not disclosed. Lentigen Corp....
BioCentury | Mar 24, 2008
Company News

Lentigen, Case Western Reserve University deal

...from the university to the MGMT gene to develop a stem-cell therapy to treat glioblastoma. Lentigen...
...Lentigen will be responsible for further clinical development and commercialization. Financial terms were not disclosed. Lentigen Corp....
Items per page:
1 - 10 of 19
BioCentury | Jul 28, 2017
Company News

Miltenyi acquires Living Pharma and its CAR T technology

...The Lentigen Technology Inc. subsidiary of Miltenyi Biotec GmbH (Bergisch Gladbach, Germany) acquired immunotherapy company Living...
...CAR (AT-CAR) engineered T cell therapy technology. The companies will continue developing AT-CAR technology using Lentigen’s...
BioCentury | Sep 8, 2014
Company News

Opus Bio, Miltenyi Biotec deal

...single-gene diseases and disorders. Miltenyi will operate the business from its newly formed U.S. subsidiary, Lentigen...
BioCentury | Aug 7, 2014
Distillery Techniques

Technology: Markers

...Aug. 7, 2014 Methods covering the production and application of BaEV lentivirus patented; licensed to Lentigen Corp....
BioCentury | May 6, 2013
Company News

Lentigen, Nanolek LLC deal

...in Kirov, Russia. Under the deal, which is expected to be signed late this year, Lentigen...
...use in producing the vaccine. The VLP-based vaccine is produced from cell lines generated using Lentigen's...
...for 2015. Nanolek builds biological production facilities in Kirov, Russia, based on nanotechnologies and nanomaterials. Lentigen Corp....
BioCentury | Feb 25, 2013
Clinical News

LG631-CD34 regulatory update

...variant of methylguanine methyltransferase ( MGMT ) is in Phase I testing for the indication. Lentigen Corp....
BioCentury | May 3, 2010
Company News

Lentigen, IAVI deal

...Lentigen and the nonprofit will design a preventative HIV vaccine using Lentigen's synthetic lentiviral mimicking technology...
...mimicking technology and conduct preclinical testing under an 18-month deal. Financial terms were not disclosed. Lentigen Corp....
BioCentury | Feb 9, 2009
Company News

Expression Therapeutics, Lentigen deal

...Expression Therapeutics will use its high expression Factor VIII technology with Lentigen's protein expression and gene...
...Ownership of IP and financial terms were not disclosed. Expression Therapeutics LLC , Tucker, Ga. Lentigen Corp....
BioCentury | May 26, 2008
Finance

Ebb & Flow

...the U.S. government. ImmunoVaccine had $250,000 in 2007 revenue, primarily from partnerships. Gene delivery company Lentigen...
BioCentury | Apr 7, 2008
Company News

Lentigen, University of Cambridge deal

...lentiviral vector platform to develop pandemic and seasonal influenza vaccines. Further terms were not disclosed. Lentigen Corp....
BioCentury | Mar 24, 2008
Company News

Lentigen, Case Western Reserve University deal

...from the university to the MGMT gene to develop a stem-cell therapy to treat glioblastoma. Lentigen...
...Lentigen will be responsible for further clinical development and commercialization. Financial terms were not disclosed. Lentigen Corp....
Items per page:
1 - 10 of 19